Open Access<p>In vitro and in vivo Anti-Tumor Effects of Pan-HER Inhibitor Varlitinib on Cholangiocarcinoma Cell Lines</p>
Author(s) -
Hasaya Dokduang,
Wassana Jamgkarn,
Bundit Promraksa,
Manida Suksawat,
Sureerat Padthaisong,
Malinee Thanee,
Jutarop Phetcharaburanin,
Nisamwat,
Sakkarn Sangkhama,
Attapol Titapun,
Narong Khuntikeo,
Poramate Klanrit,
Watcharin Loilome
Publication year - 2020
Publication title -
drug design, development and therapy
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.964
H-Index - 64
ISSN - 1177-8881
DOI - 10.2147/dddt.s250061
Subject(s) - in vivo , cell culture , chemistry , cell growth , cancer research , apoptosis , cancer , cell , pi3k/akt/mtor pathway , pharmacology , biology , biochemistry , medicine , genetics , microbiology and biotechnology
Cholangiocarcinoma (CCA) is a slowly progressing but highly aggressive malignancy. Targeting the HER protein family represents a potential therapeutic strategy for CCA treatment. The pan-HER inhibitor varlitinib is being developed for the treatment of breast cancer, gastric cancer, and biliary tract cancer, which includes CCA. This study aims to evaluate the anti-tumor effect of varlitinib on CCA using both in vitro and in vivo models.